Martin Murphy
Direktor/Vorstandsmitglied bei AUTOLUS THERAPEUTICS PLC
Vermögen: 2 Mio $ am 31.05.2024
Ursprung des Netzwerks ersten Grades von Martin Murphy
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
University of Cambridge
236
| College/University | Other Consumer Services | 236 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom.
36
| Subsidiary | Investment Managers | 36 |
| Public Company | Biotechnology | 32 | |
Achilles Therapeutics UK Ltd.
 Achilles Therapeutics UK Ltd. BiotechnologyHealth Technology Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.
10
| Public Company | Biotechnology | 10 |
Biomodal Ltd.
 Biomodal Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Epigenetix Ltd. provides epigenetic tools. Its TrueMethyl oxidative bisulfite sequencing, a novel technology that pioneers single-base resolution sequencing of the modified bases hydroxymethyl cytosine and methylcytosine. The firm's TrueMethyl enables analysis of the DNA methylome offers basic research, pharmaceutical discovery and diagnostics and TrueMethyl can be used with methylation arrays and targeted assays. The company was founded by Shankar Balasubramanian, Michael Booth and Bobby Yerramilli-Rao in 2012 and is headquartered in Cambridge, the United Kingdom.
9
| Holding Company | Miscellaneous Commercial Services | 9 |
Anaveon AG
 Anaveon AG BiotechnologyHealth Technology Anaveon AG engages in the development of immune therapies against cancer. Its compounds promote effector T-cell functions to enhance a patient?s immune system to respond to tumors. The company was founded on December 11, 2017 by Onur Boyman and Andreas Katopodis and is headquartered in Bottmingen, Switzerland.
9
| Holding Company | Biotechnology | 9 |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Neogene Therapeutics, Inc. engages in the provision T cell therapies to treat cancer. The company was founded by Ton N. M. Schumacher and Carsten Linnemann and is headquartered in New York, NY.
8
| Subsidiary | Biotechnology | 8 |
Clade Therapeutics, Inc.
 Clade Therapeutics, Inc. BiotechnologyHealth Technology Clade Therapeutics, Inc. is a company that aims to discover and deliver next-generation cell medicines to improve the lives of patients in need. Clade Therapeutics is based in Boston, MA. The company is initially focused on harnessing the potential of "cloaked" immune cells for cancer treatment. Clade Therapeutics is led by a world-class team of company builders and scientific innovators with unparalleled expertise in generating stem cell-derived adult T, NK, and B cells. The company is supported by a premier investor syndicate, including Lifesci Venture Partners, Emerson Collective, and Bristol-Myers Squibb. The company was founded by Jim Glasheen, Deepta Bhattacharya, Chris Sturgeon, Gustavo Mostoslavsky, Leandro Vetcher, Chad Cowan, and Chad Cowan has been the CEO since incorporation.
8
| Holding Company | Biotechnology | 8 |
Autolus Ltd.
 Autolus Ltd. BiotechnologyHealth Technology Autolus Ltd. provides biopharmaceutical services. It focuses on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. The company was founded by Martin Pule and is headquartered in White City, the United Kingdom.
7
| Subsidiary | Biotechnology | 7 |
MVM Partners LLP
 MVM Partners LLP Investment ManagersFinance MVM Partners LLP (MVM Partners) is a venture capital firm founded in 1997. The firm is headquartered in London, the United Kingdom.
6
| Private Company | Investment Managers | 6 |
Quell Therapeutics Ltd.
 Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom.
6
| Holding Company | Pharmaceuticals: Major | 6 |
Blue Earth Diagnostics Ltd.
 Blue Earth Diagnostics Ltd. Medical/Nursing ServicesHealth Services Blue Earth Diagnostics Ltd. engages in the development and commercialization of positron emission tomography imaging agents. It focuses on the molecular imaging diagnostics. The company was founded in March 2014 and is headquartered in Oxford, the United Kingdom.
4
| Subsidiary | Medical/Nursing Services | 4 |
Resolution Therapeutics Ltd.
 Resolution Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Resolution Therapeutics Ltd. operates as a macrophage cell therapy company. The company was founded on December 14, 2017 and is headquartered in London, the United Kingdom.
4
| Holding Company | Miscellaneous Commercial Services | 4 |
Azeria Therapeutics Ltd.
 Azeria Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Azeria Therapeutics Ltd. engages in the research and development of pharmaceutical products. It develops treatments for hormone resistance that targets breast and prostate cancer patients. The company was founded by Jason Carroll in 2017 and is headquartered in Cambridge, the United Kingdom.
3
| Holding Company | Pharmaceuticals: Major | 3 |
Syncona Investment Management Ltd.
 Syncona Investment Management Ltd. Investment ManagersFinance Syncona Investment Management Ltd. (Syncona) is the asset management subsidiary of Syncona Ltd. in Great Britain. Headquartered in London, the firm was co-founded by Martin Murphy alongside The Wellcome Trust. Syncona is focused on founding, building and funding a portfolio of global leaders in life science.
3
| Subsidiary | Investment Managers | 3 |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom.
2
| Private Company | Pharmaceuticals: Major | 2 |
Syncona Discovery Ltd.
 Syncona Discovery Ltd. Financial ConglomeratesFinance Part of Syncona Ltd., Syncona Discovery Ltd. is a British company that provides investment services. The company is based in London, UK. Syncona Discovery was founded in 2013.
1
| Subsidiary | Financial Conglomerates | 1 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Martin Murphy
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member Chief Executive Officer Founder Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Graduate Degree Doctorate Degree Undergraduate Degree | |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Biotechnology | Director/Board Member Chief Executive Officer Director/Board Member General Counsel | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| University of Pennsylvania | College/University | Graduate Degree Undergraduate Degree Undergraduate Degree | |
| University College London | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Biotechnology | Chairman Chairman Director/Board Member | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Private Equity Investor | |
| Forcefield Therapeutics Ltd. | Chairman Chief Executive Officer Director/Board Member | ||
| KITE PHARMA INC | Biotechnology | Founder Director of Finance/CFO Director/Board Member | |
| JAZZ PHARMACEUTICALS PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| SYNCONA LIMITED | Investment Trusts/Mutual Funds | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Corporate Officer/Principal Undergraduate Degree Doctorate Degree | |
| Stanford University | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
Abingworth Management Ltd.
 Abingworth Management Ltd. Investment ManagersFinance Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom. | Investment Managers | Director/Board Member Corporate Officer/Principal | |
| AMGEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Avillion LLP
 Avillion LLP Pharmaceuticals: MajorHealth Technology Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer | |
Duke University
 Duke University Other Consumer ServicesConsumer Services Duke University is an academic university that offers undergraduate, graduate and professional programs. It also has publications and research services. The university was founded in 1838 and is headquartered in Durham, NC. | College/University | Doctorate Degree Undergraduate Degree | |
| London Business School | College/University | Masters Business Admin Undergraduate Degree | |
| IMMUNOMEDICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer Director/Board Member | |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Pharmaceuticals: Major | Chairman Director of Finance/CFO | |
Mariana Oncology, Inc.
 Mariana Oncology, Inc. BiotechnologyHealth Technology Mariana Oncology, Inc., also known as Curie Therapeutics, is a radiopharmaceuticals company that specializes in developing safe and effective targeted radiopharmaceuticals for cancer treatment. The company is based in Woburn, MA and was founded by Simon Read, who has been the CEO since incorporation. The company's radiopharmaceuticals are designed to deliver alpha and beta-emitting radionuclide payloads to carefully selected biological targets. | Biotechnology | Director/Board Member Director of Finance/CFO | |
| ABLYNX | Biotechnology | Director/Board Member Chief Executive Officer | |
| EPIGENOMICS AG | Medical Specialties | Director/Board Member Director/Board Member | |
| RENEURON GROUP PLC | Pharmaceuticals: Major | Chairman Chairman | |
| ALDER BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| New York University School of Law | College/University | Graduate Degree Graduate Degree | |
| ILLUMINA, INC. | Biotechnology | Chief Operating Officer Investor Relations Contact | |
| BLUEBIRD BIO, INC. | Biotechnology | Director of Finance/CFO Director/Board Member | |
| ITEOS THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022. | Investment Managers | Director/Board Member Private Equity Investor | |
| UROGEN PHARMA LTD. | Biotechnology | Director/Board Member Director/Board Member | |
VV Manager LLC
 VV Manager LLC Investment ManagersFinance VV Manager LLC (Vida Ventures) is a venture capital firm founded in 2017 by Arie Belldegrun, Arjun Goyal and Stefan Vitorovic. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Consultant / Advisor Private Equity Investor | |
Hermes Growth Partners Ltd.
 Hermes Growth Partners Ltd. Investment ManagersFinance Hermes Growth Partners Ltd (Hermes Growth Partners) is a growth equity firm founded in 2011 by Bobby Yerramilli-Rao and Juan Villalonga. The firm is headquartered in London. | Investment Managers | Founder Director of Finance/CFO | |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
| POLAREAN IMAGING PLC | Medical Specialties | Director/Board Member Chairman | |
| NATERA, INC. | Medical Specialties | Director/Board Member Director/Board Member | |
Ahren Innovation Capital LLP
 Ahren Innovation Capital LLP Investment ManagersFinance Ahren Innovation Capital LLP (Ahren) is a venture capital firm founded in 2017 by Alice Newcombe-Ellis. The firm is headquartered in Cambridge, UK. | Investment Managers | Private Equity Investor Founder | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Founder Corporate Officer/Principal | |
| VBI VACCINES INC. | Biotechnology | Director/Board Member Director/Board Member | |
OMass Therapeutics Ltd.
 OMass Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services OMass Therapeutics Ltd. develops native mass spectrometry platform The company was founded by Dame Carol Robinson and is headquartered in Oxford, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
| MERCK & CO., INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services NightstaRx Ltd. develops and commercializes therapies for retinal dystrophies. It offers retinal gene therapy that provides one-time cure for choroideremia (a rare inherited cause of blindness) and other retinal dystrophies. The company was founded by Robert MacLaren, Miguel Seabra, and Matthew During in January 2014 and is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| University of Cape Town | College/University | Undergraduate Degree Undergraduate Degree |
Statistik
International
| Vereinigte Staaten | 26 |
| Vereinigtes Königreich | 17 |
| Schweiz | 4 |
| Deutschland | 3 |
| Norwegen | 2 |
Sektoral
| Health Technology | 30 |
| Consumer Services | 12 |
| Finance | 6 |
| Commercial Services | 3 |
| Miscellaneous | 2 |
Operativ
| Director/Board Member | 507 |
| Corporate Officer/Principal | 146 |
| Independent Dir/Board Member | 114 |
| Chairman | 87 |
| Founder | 63 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Johnson Chen | 42 |
| Simon Holden | 40 |
| Kapil Dhingra | 39 |
| Ran Nussbaum | 38 |
| Roelof Botha | 37 |
| Edwin Moses | 35 |
| William Young | 32 |
| Ken Galbraith | 30 |
| John Bradshaw | 27 |
| David Tanen | 25 |
| Daniel Vasella | 25 |
| John Berriman | 24 |
| Bryan Geoffrey Morton | 22 |
| Gail Marcus | 21 |
| Shen Yi Thio | 20 |
- Börse
- Insiders
- Martin Murphy
- Unternehmensverbindungen